<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28105087</article-id><article-id pub-id-type="pmc">5228331</article-id><article-id pub-id-type="doi">10.3892/etm.2016.3812</article-id><article-id pub-id-type="publisher-id">ETM-0-0-3812</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Long-term prognostic analysis of early interventional therapy for lower extremity deep venous thrombosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qiang</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3812">1</xref><xref rid="c1-etm-0-0-3812" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Zongxue</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-3812">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jinjun</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3812">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3812">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3812">1</xref></contrib></contrib-group><aff id="af1-etm-0-0-3812"><label>1</label>Department of Vascular Surgery, The Affiliated Qingdao Hiser Hospital of Qingdao University, Qingdao, Shandong 266033, P.R. China</aff><aff id="af2-etm-0-0-3812"><label>2</label>Department of Internal Medicine, The Third People's Hospital of Qingdao, Qingdao, Shandong 266033, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-3812"><italic>Correspondence to</italic>: Dr Qiang Li, Department of Vascular Surgery, The Affiliated Qingdao Hiser Hospital of Qingdao University, 4 Renmin Road, Qingdao, Shandong 266033, P.R. China, E-mail: <email>ll30149004chengc@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>18</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>10</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>12</volume><issue>6</issue><fpage>3545</fpage><lpage>3548</lpage><history><date date-type="received"><day>04</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Li et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The aim of the present study was to observe the long-term prognostic value of early interventional therapy for lower extremity deep venous thrombosis (LDVT). In total, 85 patients diagnosed with LDVT for the first time were consecutively selected (identified course of disease was &#x0003c;3 months), and were divided into the control group with 43 cases and the observation group with 42 cases according to different therapeutic methods. The control group received anticoagulation therapy and thrombolysis, or integrated surgical thrombectomy, a conventional open operation, while the observation group received comprehensive treatment, combining endovascular catheter-directed thrombolysis and thrombectomy. The therapeutic effects were compared. After treatment, the differences in circumference of the thigh and shank between the affected and unaffected extremities, and vein dysfunction score of the two groups were decreased compared with before treatment. In addition, the above indexes of the observation group were significantly lower than in the control group (P&#x0003c;0.05). The clinical effective rate and effective extent of the observation group were higher than those of the control group, and the differences were statistically significant (P&#x0003c;0.05). The occurrence rate of post-thrombotic syndrome in the observation group was lower than that of the control group, and there was no difference in comparison of grading. The recurrence rate and restenosis rate of the observation group were lower than in the control group, while the patency rate of the observation group was higher than that of the control group, and the differences were statistically significant (P&#x0003c;0.05). In conclusion, early catheter-directed invention of thrombolysis with thrombectomy for LDVT has good clinical effect in the short-term and long-term.</p></abstract><kwd-group><kwd>endovascular interventional treatment</kwd><kwd>deep venous thrombosis</kwd><kwd>post-thrombotic syndrome</kwd><kwd>thrombolysis</kwd><kwd>anticoagulation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Lower extremity deep venous thrombosis (LDVT) is caused by various factors. Blood abnormally pools in the deep veins, forming a thrombus and the vena cava is partially or completely blocked, leading to a block of blood return (<xref rid="b1-etm-0-0-3812" ref-type="bibr">1</xref>,<xref rid="b2-etm-0-0-3812" ref-type="bibr">2</xref>). The high-risk population are mostly those with severe injury, in gestation, with peripheral vessel lesions and confined to bed for prolonged periods of time (<xref rid="b3-etm-0-0-3812" ref-type="bibr">3</xref>). If patients are not treated as early as possible, their affected extremities may appear with complete or partial dysfunction. In severe cases, acute pulmonary embolism (PE) caused by dislodging of a clot may occur, and most of the patients may develop post-thrombotic syndrome (PTS) (<xref rid="b4-etm-0-0-3812" ref-type="bibr">4</xref>).</p><p>As endovascular intervention technology has improved, early endovascular intervention has become an important supplementary method for thrombolysis, anticoagulation therapy, and surgical thrombectomy (<xref rid="b5-etm-0-0-3812" ref-type="bibr">5</xref>). Previous findings have shown that interventional therapy has many advantages, such as causing small trauma, is safe and reliable, and is comparable and possibly superior to the effect of medication alone or the combined effect of medicine and surgery (<xref rid="b6-etm-0-0-3812" ref-type="bibr">6</xref>,<xref rid="b7-etm-0-0-3812" ref-type="bibr">7</xref>). Due to different sample sizes and follow-up times, the effects of interventional therapy were different (<xref rid="b8-etm-0-0-3812" ref-type="bibr">8</xref>,<xref rid="b9-etm-0-0-3812" ref-type="bibr">9</xref>). Whether early intervention of thrombolysis is an effective first-line treatment for LDVT is not yet known.</p><p>In the present study, we analyzed the effect of early endovascular intervention on LDVT, aiming to provide a reference for treatment options.</p></sec><sec sec-type="subjects|methods"><title>Patients and methods</title><sec><title/><sec><title>Patients</title><p>Eighty-five patients diagnosed with LDVT for the first time between January 2013 and January 2016 at the Affiliated Qingdao Hiser Hospital of Qingdao University, were consecutively selected. The identified course of disease was &#x0003c;3 months as confirmed by lower extremity venous ultrasonography or venography. The exclusion criteria included: Organized thrombi; complications with other lower extremity venous lesions, such as phlebophlogosis, and absence of venous valves in the lower extremities; vena cava thrombosis; acute PE; lower extremity venous malformation that could not be punctured; contrast agent allergy; complications with underlying diseases, such as of the heart, liver, kidney, lung, brain and other organs; and secondary to other primary causes such as field activity, pregnancy, and early postoperative fracture.</p><p>Approval for the study was obtained by the Ethics Committee of the Affiliated Qingdao Hiser Hospital of Qingdao University. Written informed consent from patients or their families was obtained. The patients were divided into the control group with 43 cases and the observation group with 42 cases, according to the different therapeutic methods. The baseline parameters of the patients from the two groups was comparable (<xref rid="tI-etm-0-0-3812" ref-type="table">Table I</xref>).</p></sec><sec><title>Research methods</title><p>After admission, the patients from the two groups underwent prostration with the affected extremity raised up 15&#x02013;30&#x000b0; to improve microcirculation. Patients in the control group received medicine alone or medicine combined with conventional open surgery for thrombus extraction. The anticoagulant drugs used were subcutaneous injection of 100 IU/kg low molecular heparin sodium, once every 12 h, and after 5 days, warfarin sodium tablet thrombolysis treatment was adopted at 2.5 mg/day. On the 8th day, low molecular heparin sodium was stopped, and patients received oral warfarin sodium tablets at 2.5 mg/day for at least 6 months. Close monitoring of coagulation function was performed during treatment.</p><p>The observation group received endovascular interventional treatment in the supine position, with a venipuncture approach through the unaffected side to insert a catheter sheath after local anesthesia, to observe if there was stenosis and thrombosis by inferior vena cava angiography. An inferior vena cava filter was placed, and the catheter was inserted into the iliofemoral vein of the affected side with assistance of a guide wire. Thrombus accumulation of the proximal part was monitored by radiography and thrombolysis catheters were replaced in time to fix the side holes of the head-end fully into the thrombus. Urokinase (50 WU/day) was pumped through the catheter for 24 h, which could have been integrated with thrombectomy. According to the state of thrombolysis demonstrated by venography after 1 week, the hole on the side of the catheter head was adjusted with a coagulation function monitor and the iliac vein was treated with stent implantation or angioplasty.</p></sec><sec><title>Observational indexes and evaluation methods</title><p>The difference in circumference of the thigh and shank between the affected and unaffected extremities, and vein dysfunction score (VDS) of the two groups were analyzed and compared with the values before treatment. The standards for VDS were: No pain but with some symptoms, including skin itch and muscle spasm was assigned 0 points; clinical symptoms, but with normal daily activities and no need for elastic webbing support treatment was assigned 1 point; clinical symptoms, with need for elastic webbing support and raised affected extremity working normally was assigned 2 points; clinical symptoms, with need for elastic webbing support and raised affected extremity working abnormally was assigned 3 points.</p><p>Clinical efficiency rates were compared. The evaluation standards for therapeutic effect were: Smooth and unobstructed vein wall detected by color Doppler ultrasound with no thrombus was considered class I recovery (excellent); smooth but rough vein wall detected by color Doppler ultrasound, with blood vessel diameter &#x0003e;70% was considered class II (good); thrombus remains shown by color Doppler ultrasound, with blood vessel diameter &#x02264;70% was considered class III (effective); symptoms did not improve or were worse and the deep vein was obstructed was considered class VI (invalid).</p><p>The incidence of PTS during the perioperative period and follow-up was compared, applying the Villalta score to mark the level of PTS from class I&#x02013;III, and the score from no symptoms to severe (0&#x02013;3 points) (<xref rid="tII-etm-0-0-3812" ref-type="table">Table II</xref>).</p><p>The follow-up rates of recurrence, restenosis, and unobstruction were compared. The rate of unobstruction referred to lower extremity deep veins, and the inferior vena cava system (common femoral veins, inferior vena cava segment, vena iliaca externa, common iliac vein, popliteal vein, and upper and lower segment of the superficial femoral vein). Rate of unobstruction was graded as follows: Completely unobstructed was assigned 0 points; partially unobstructed was assigned 1 point; thrombus was found with obstruction was assigned 2 points. The score for rate of unobstruction was the sum of scores for seven vein segments. Rate of vein unobstruction = score (before treatment - after treatment) score/score before treatment &#x000d7; 100%.</p></sec><sec><title>Statistical analysis</title><p>SPSS 19.0 software was used for data analysis (IBM SPSS, Armonk, NY, USA). Measurement data were presented as mean &#x000b1; standard deviation. Comparisons between groups were by independent sample t-test. Countable data are presented as rate, and comparisons between groups were by &#x003c7;<sup>2</sup> test. For ranked data, non-parametric rank-sum test was adopted. P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Comparison of difference of circumference of the thigh and shank between affected and unaffected extremities, and VDS</title><p>After treatment, the difference in circumference of the thigh and shank between the affected and unaffected extremities, and VDS of the two groups decreased compared with before treatment. The differences were significantly lower in the observation group compared with the control group (P&#x0003c;0.05) (<xref rid="tIII-etm-0-0-3812" ref-type="table">Table III</xref>).</p></sec><sec><title>Comparison of clinical effective rate and PTS occurrence rate</title><p>The clinical effective rate and effective rate of the observation group was significantly higher than that of the control group (P&#x0003c;0.05). The follow-up period of the two groups was 3&#x02013;35 months, with median time of 18.5 months. The occurrence rate of PTS in the observation group was lower than that of the control group (P&#x0003c;0.05) (<xref rid="tIV-etm-0-0-3812" ref-type="table">Table IV</xref>).</p></sec><sec><title>Comparison of follow-up rates of recurrence, restenosis, and patency</title><p>The recurrence rate and restenosis rate of the observation group were lower than in the control group, while the patency rate of the observation group was higher than that of the control group, and the differences were statistically significant (P&#x0003c;0.05) (<xref rid="tV-etm-0-0-3812" ref-type="table">Table V</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The treatment of LDVT primarily includes early anticoagulation, thrombectomy, and thrombolysis. However, the PTS occurrence rate for long-term prognosis is unsatisfactory. Catheter-directed thrombolysis is a new form of interventional therapy, which can transport thrombolytic drugs (i.e., urokinase) to the thrombus through the thrombolytic catheter, thereby reducing the metabolism of urokinase which occurs during the conventional transport processes to promote high drug concentration. This results in an increase of drug utilization rate (<xref rid="b10-etm-0-0-3812" ref-type="bibr">10</xref>). The head of the thrombolysis catheter has many holes on different sides and thrombolytic drugs can spray from these holes via micro-pump, leading to increased contact between drugs and the thrombus, so that the number of activated plasminogen molecules in the thrombus increases, which can maintain the local drug concentration in the thrombus for a long time (<xref rid="b11-etm-0-0-3812" ref-type="bibr">11</xref>). Similarly, it can decrease the degree of thrombus organization, which is beneficial for complete dissolution of the thrombus (<xref rid="b12-etm-0-0-3812" ref-type="bibr">12</xref>).</p><p>PTS is a very common complication in the long-term, and is a phenomenon that occurs during the recovery phase of deep veins after thrombosis. Blood countercurrent following recanalization results in high pressure and congestion of the vein, leading to shallow varicose veins, limb swelling pain, pigmentation, and skin ulcers (<xref rid="b13-etm-0-0-3812" ref-type="bibr">13</xref>). Whether the deep vein is unobstructed or not directly affects prognosis, especially for the thin iliac vein wall, with poor elasticity that easily loses its shape when pressed. Additionally, reocclusion and restenosis can cause recurrence of deep venous thrombosis (<xref rid="b14-etm-0-0-3812" ref-type="bibr">14</xref>). Stent implantation by comprehensive interventional treatment can maintain blood flow velocity and volume to guarantee long-term rate of patency, thus reducing the degree and incidence of PTS, which has great significance for the long-term prognosis of LDVT (<xref rid="b15-etm-0-0-3812" ref-type="bibr">15</xref>,<xref rid="b16-etm-0-0-3812" ref-type="bibr">16</xref>).</p><p>The present study has shown that the difference in circumference of the thigh and shank between the affected and unaffected extremities, and VDS of the observation group decreased significantly after treatment. The clinical effective rate and effective extent of the observation group increased. PTS occurrence decreased and the rates of recurrence and restenosis of the observation group decreased significantly. The rate of patency increased as well. The differences were statistically significant. In conclusion, early invention of thrombolysis combined with thrombectomy for deep venous thrombosis has good clinical effect in the short-term and long-term, with reduction of PTS. The combined treatment is safe, effective, and worthy of clinical promotion.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-0-0-3812"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durbec</surname><given-names>O</given-names></name><name><surname>Viviand</surname><given-names>X</given-names></name><name><surname>Potie</surname><given-names>F</given-names></name><name><surname>Vialet</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name></person-group><article-title>Lower extremity deep vein thrombosis: A prospective, randomized, controlled trial in comatose or sedated patients undergoing femoral vein catheterization</article-title><source>Crit Care Med</source><volume>25</volume><fpage>1982</fpage><lpage>1985</lpage><year>1997</year><pub-id pub-id-type="doi">10.1097/00003246-199712000-00013</pub-id><pub-id pub-id-type="pmid">9403746</pub-id></element-citation></ref><ref id="b2-etm-0-0-3812"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>DJ</given-names></name><name><surname>Alikhan</surname><given-names>R</given-names></name><name><surname>Gishen</surname><given-names>P</given-names></name><name><surname>Sidhu</surname><given-names>PS</given-names></name></person-group><article-title>Variations in lower limb venous anatomy: Implications for US diagnosis of deep vein thrombosis</article-title><source>Radiology</source><volume>228</volume><fpage>443</fpage><lpage>448</lpage><year>2003</year><pub-id pub-id-type="doi">10.1148/radiol.2282020411</pub-id><pub-id pub-id-type="pmid">12821771</pub-id></element-citation></ref><ref id="b3-etm-0-0-3812"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roupie</surname><given-names>AL</given-names></name><name><surname>Dossier</surname><given-names>A</given-names></name><name><surname>Goulenok</surname><given-names>T</given-names></name><name><surname>Perozziello</surname><given-names>A</given-names></name><name><surname>Papo</surname><given-names>T</given-names></name><name><surname>Sacre</surname><given-names>K</given-names></name></person-group><article-title>First venous thromboembolism in admitted patients younger than 50 years old</article-title><source>Eur J Intern Med</source><volume>2323</volume><fpage>14</fpage><lpage>15</lpage><year>2016</year></element-citation></ref><ref id="b4-etm-0-0-3812"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>V&#x000e1;zquez L</given-names></name><name><surname>Santos</surname><given-names>Arment&#x000ed;a E</given-names></name><name><surname>de la Fuente</surname><given-names>Aguado J</given-names></name></person-group><article-title>Post-thrombotic syndrome</article-title><source>Rev Clin Esp</source><volume>18</volume><fpage>16</fpage><lpage>17</lpage><year>2016</year><comment>(In Spanish)</comment></element-citation></ref><ref id="b5-etm-0-0-3812"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saroukhani</surname><given-names>A</given-names></name><name><surname>Ravari</surname><given-names>H</given-names></name><name><surname>Rad</surname><given-names>M Pezeshki</given-names></name></person-group><article-title>Effects of intravenous and catheter directed thrombolytic therapy with recombinant tissue plasminogen activator (Alteplase) in non-traumatic acute limb ischemia; a randomized double-blind clinical trial</article-title><source>Bull Emerg Trauma</source><volume>3</volume><fpage>86</fpage><lpage>92</lpage><year>2015</year><pub-id pub-id-type="pmid">27162909</pub-id></element-citation></ref><ref id="b6-etm-0-0-3812"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sag</surname><given-names>S</given-names></name><name><surname>Nas</surname><given-names>OF</given-names></name><name><surname>Kaderli</surname><given-names>AA</given-names></name><name><surname>Ozdemir</surname><given-names>B</given-names></name><name><surname>Baran</surname><given-names>&#x00130;</given-names></name><name><surname>Erdo&#x0011f;an</surname><given-names>C</given-names></name><name><surname>Gullulu</surname><given-names>S</given-names></name><name><surname>Hakyemez</surname><given-names>B</given-names></name><name><surname>Aydinlar</surname><given-names>A</given-names></name></person-group><article-title>Catheter-directed ultrasound-accelerated thrombolysis may be life-saving in patients with massive pulmonary embolism after failed systemic thrombolysis</article-title><source>J Thromb Thrombolysis</source><volume>29</volume><fpage>12</fpage><lpage>13</lpage><year>2016</year></element-citation></ref><ref id="b7-etm-0-0-3812"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>JY</given-names></name><name><surname>Zhu</surname><given-names>QH</given-names></name><name><surname>Luo</surname><given-names>MH</given-names></name><name><surname>Zhou</surname><given-names>CY</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>XF</given-names></name></person-group><article-title>Clinical significance of monitoring coagulation- and fibrinolysis-related indexes during catheter-directed thrombolysis for acute lower-extremity deep venous thrombosis</article-title><source>Nan Fang Yi Ke Da Xue Xue Bao</source><volume>36</volume><fpage>588</fpage><lpage>591</lpage><year>2016</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">27113193</pub-id></element-citation></ref><ref id="b8-etm-0-0-3812"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dilektasli</surname><given-names>A Gorek</given-names></name><name><surname>Cetinoglu</surname><given-names>E Demirdogen</given-names></name><name><surname>Acet</surname><given-names>NA</given-names></name><name><surname>Erdogan</surname><given-names>C</given-names></name><name><surname>Ursavas</surname><given-names>A</given-names></name><name><surname>Ozkaya</surname><given-names>G</given-names></name><name><surname>Coskun</surname><given-names>F</given-names></name><name><surname>Karadag</surname><given-names>M</given-names></name><name><surname>Ege</surname><given-names>E</given-names></name></person-group><article-title>Catheter-directed therapy in acute pulmonary embolism with right ventricular dysfunction: a promising modality to provide early hemodynamic recovery</article-title><source>Med Sci Monit</source><volume>22</volume><fpage>1265</fpage><lpage>1273</lpage><year>2016</year><pub-id pub-id-type="doi">10.12659/MSM.897617</pub-id><pub-id pub-id-type="pmid">27081754</pub-id></element-citation></ref><ref id="b9-etm-0-0-3812"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundar</surname><given-names>G</given-names></name><name><surname>Keshava</surname><given-names>SN</given-names></name><name><surname>Moses</surname><given-names>V</given-names></name><name><surname>Chiramel</surname><given-names>GK</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Mammen</surname><given-names>S</given-names></name><name><surname>Aggarwal</surname><given-names>S</given-names></name><name><surname>Stephen</surname><given-names>E</given-names></name></person-group><article-title>Outcomes of catheter-directed treatment of lower extremity deep vein thrombosis of patients presenting to a tertiary care hospital</article-title><source>Indian J Radiol Imaging</source><volume>26</volume><fpage>73</fpage><lpage>80</lpage><year>2016</year><pub-id pub-id-type="doi">10.4103/0971-3026.178340</pub-id><pub-id pub-id-type="pmid">27081228</pub-id></element-citation></ref><ref id="b10-etm-0-0-3812"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>JW</given-names></name><name><surname>Choi</surname><given-names>HC</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Cho</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JD</given-names></name><name><surname>Kim</surname><given-names>HC</given-names></name></person-group><article-title>Comparison between systemic and catheter thrombolysis in patients with pulmonary embolism</article-title><source>Am J Emerg Med</source><volume>34</volume><fpage>985</fpage><lpage>988</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.ajem.2016.02.037</pub-id><pub-id pub-id-type="pmid">27033736</pub-id></element-citation></ref><ref id="b11-etm-0-0-3812"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>XQ</given-names></name><name><surname>Sang</surname><given-names>HF</given-names></name><name><surname>Qian</surname><given-names>AM</given-names></name><name><surname>Rong</surname><given-names>JJ</given-names></name><name><surname>Li</surname><given-names>CL</given-names></name></person-group><article-title>Mid-term outcome of endovascular treatment for acute lower extremity deep venous thrombosis</article-title><source>Phlebology</source><volume>27</volume><fpage>54</fpage><lpage>55</lpage><year>2016</year></element-citation></ref><ref id="b12-etm-0-0-3812"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Goldberg</surname><given-names>HD</given-names></name><name><surname>Zubkus</surname><given-names>D</given-names></name><name><surname>Shears</surname><given-names>LL</given-names></name><name><surname>Kaczorowski</surname><given-names>DJ</given-names></name></person-group><article-title>Successful management of cardiac arrest due to pulmonary embolus using extracorporeal membrane oxygenation and ultrasound-accelerated catheter-directed thrombolysis</article-title><source>Ann Thorac Surg</source><volume>101</volume><fpage>e107</fpage><lpage>e109</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.athoracsur.2015.10.023</pub-id><pub-id pub-id-type="pmid">27000611</pub-id></element-citation></ref><ref id="b13-etm-0-0-3812"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>NA</given-names></name><name><surname>Sophie</surname><given-names>Z</given-names></name><name><surname>Zafar</surname><given-names>F</given-names></name><name><surname>Soares</surname><given-names>D</given-names></name><name><surname>Naz</surname><given-names>I</given-names></name></person-group><article-title>Predictors for the development of post-thrombotic syndrome in patients with primary lower limb deep venous thrombosis: a case-control study</article-title><source>Vascular</source><volume>15</volume><fpage>65</fpage><lpage>66</lpage><year>2016</year></element-citation></ref><ref id="b14-etm-0-0-3812"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgstaller</surname><given-names>JM</given-names></name><name><surname>Steurer</surname><given-names>J</given-names></name><name><surname>Held</surname><given-names>U</given-names></name><name><surname>Amann-Vesti</surname><given-names>B</given-names></name></person-group><article-title>Efficacy of compression stockings in preventing post-thrombotic syndrome in patients with deep venous thrombosis: a systematic review and meta-analysis</article-title><source>Vasa</source><volume>45</volume><fpage>141</fpage><lpage>147</lpage><year>2016</year><pub-id pub-id-type="doi">10.1024/0301-1526/a000508</pub-id><pub-id pub-id-type="pmid">27058800</pub-id></element-citation></ref><ref id="b15-etm-0-0-3812"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ten Cate-Hoek</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of compression for the prevention of post-thrombotic syndrome: an unsolved clinical conundrum Comment on Burgstaller et al, p141-147</article-title><source>Vasa</source><volume>45</volume><fpage>85</fpage><lpage>86</lpage><year>2016</year><pub-id pub-id-type="doi">10.1024/0301-1526/a000502</pub-id><pub-id pub-id-type="pmid">27058794</pub-id></element-citation></ref><ref id="b16-etm-0-0-3812"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>A</given-names></name><name><surname>G&#x000e1;ndara</surname><given-names>E</given-names></name></person-group><article-title>Statins for the prevention of post-thrombotic syndrome in patients with deep vein thrombosis. Comment on San Norberto et al, p133-140</article-title><source>Vasa</source><volume>45</volume><fpage>83</fpage><lpage>84</lpage><year>2016</year><pub-id pub-id-type="doi">10.1024/0301-1526/a000501</pub-id><pub-id pub-id-type="pmid">27058793</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-etm-0-0-3812" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of baseline parameters of the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Parameters</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control group (n=43)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Observation group (n=42)</th><th align="center" valign="bottom" rowspan="1" colspan="1">t/&#x003c7;<sup>2</sup></th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">M/F</td><td align="center" valign="top" rowspan="1" colspan="1">28/15</td><td align="center" valign="top" rowspan="1" colspan="1">30/12</td><td align="center" valign="top" rowspan="1" colspan="1">0.391</td><td align="center" valign="top" rowspan="1" colspan="1">0.532</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">46.8&#x000b1;12.3</td><td align="center" valign="top" rowspan="1" colspan="1">47.5&#x000b1;13.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.237</td><td align="center" valign="top" rowspan="1" colspan="1">0.628</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Average duration (weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">4.8&#x000b1;2.3</td><td align="center" valign="top" rowspan="1" colspan="1">5.0&#x000b1;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.266</td><td align="center" valign="top" rowspan="1" colspan="1">0.613</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Central type thrombus</td><td align="center" valign="top" rowspan="1" colspan="1">31 (72.1)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (81.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.927</td><td align="center" valign="top" rowspan="1" colspan="1">0.336</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mixed type thrombus</td><td align="center" valign="top" rowspan="1" colspan="1">12 (27.9)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (19.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Average length of thrombus (cm)</td><td align="center" valign="top" rowspan="1" colspan="1">2.6&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">2.7&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.324</td><td align="center" valign="top" rowspan="1" colspan="1">0.637</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Average diameter (mm)</td><td align="center" valign="top" rowspan="1" colspan="1">5.3&#x000b1;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">5.2&#x000b1;2.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.421</td><td align="center" valign="top" rowspan="1" colspan="1">0.456</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Traumatism</td><td align="center" valign="top" rowspan="1" colspan="1">18 (41.9)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (40.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.144</td><td align="center" valign="top" rowspan="1" colspan="1">0.931</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postoperation</td><td align="center" valign="top" rowspan="1" colspan="1">12 (27.9)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (31.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Long-term bedridden</td><td align="center" valign="top" rowspan="1" colspan="1">16 (37.2)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (42.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-3812"><p>M, male; F, female.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-etm-0-0-3812" orientation="portrait" position="float"><label>Table II.</label><caption><p>PTS grading.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Signs and symptoms</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class I (light)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class II (intermediate)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class III (severe)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Painful symptoms</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Muscle spasm</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heaviness</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Skin itch</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Paresthesia</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pretibial myxedema</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hyperpigmentation</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red skin color</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Skin sclerosis</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gastrocnemius muscle pain</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Varicosity</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Venous ulceration</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-etm-0-0-3812"><p>PTS, post-thrombotic syndrome.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-etm-0-0-3812" orientation="portrait" position="float"><label>Table III.</label><caption><p>Comparison of difference in perimeter of thigh and shank between affected and unaffected extremities, and VDS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">Difference in perimeter of thigh (cm)</th><th align="center" valign="bottom" colspan="2" rowspan="1">Difference in perimeter of shank (cm)</th><th align="center" valign="bottom" colspan="2" rowspan="1">VDS (points)</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Before treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">After treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">After treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">After treatment</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">3.63&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">2.15&#x000b1;1.02</td><td align="center" valign="top" rowspan="1" colspan="1">1.95&#x000b1;0.36</td><td align="center" valign="top" rowspan="1" colspan="1">1.26&#x000b1;0.33</td><td align="center" valign="top" rowspan="1" colspan="1">2.2&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x000b1;0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation</td><td align="center" valign="top" rowspan="1" colspan="1">3.74&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.86&#x000b1;0.24</td><td align="center" valign="top" rowspan="1" colspan="1">2.01&#x000b1;0.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.53&#x000b1;0.15</td><td align="center" valign="top" rowspan="1" colspan="1">2.1&#x000b1;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.6&#x000b1;0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-test</td><td align="center" valign="top" rowspan="1" colspan="1">0.234</td><td align="center" valign="top" rowspan="1" colspan="1">5.928</td><td align="center" valign="top" rowspan="1" colspan="1">0.326</td><td align="center" valign="top" rowspan="1" colspan="1">6.082</td><td align="center" valign="top" rowspan="1" colspan="1">0.993</td><td align="center" valign="top" rowspan="1" colspan="1">5.483</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.727</td><td align="center" valign="top" rowspan="1" colspan="1">0.016</td><td align="center" valign="top" rowspan="1" colspan="1">0.528</td><td align="center" valign="top" rowspan="1" colspan="1">0.013</td><td align="center" valign="top" rowspan="1" colspan="1">0.124</td><td align="center" valign="top" rowspan="1" colspan="1">0.019</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-etm-0-0-3812"><p>VDS, vein dysfunction score.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-etm-0-0-3812" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Comparison of clinical effective rate and PTS occurrence rate [n (%)].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class I</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class II</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class III</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class IV</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effective rate</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class I</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class II</th><th align="center" valign="bottom" rowspan="1" colspan="1">Class III</th><th align="center" valign="bottom" rowspan="1" colspan="1">PTS occurrence rate</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">2 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (16.3)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (46.5)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (32.6)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (67.4)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (7.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (16.3)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (16.3)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (39.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation</td><td align="center" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="top" rowspan="1" colspan="1">6 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (33.3)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (38.1)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (85.7)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2(4.8)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (19.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Z/&#x003c7;<sup>2</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" colspan="2" rowspan="1">8.196</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">3.943</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.274</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4.295</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" colspan="2" rowspan="1">0.042</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.047</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.529</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.038</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-etm-0-0-3812"><p>PTS, post-thrombotic syndrome.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tV-etm-0-0-3812" orientation="portrait" position="float"><label>Table V.</label><caption><p>Comparison of follow-up recurrence rate, restenosis rate and patency rate [n (%)].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Recurrencet rate</th><th align="center" valign="bottom" rowspan="1" colspan="1">Restenosis rate</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patency rate</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">10 (23.3)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (34.9)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (58.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation</td><td align="center" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="top" rowspan="1" colspan="1">3 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">33 (78.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4.258</td><td align="center" valign="top" rowspan="1" colspan="1">5.143</td><td align="center" valign="top" rowspan="1" colspan="1">4.092</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.039</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td><td align="center" valign="top" rowspan="1" colspan="1">0.043</td></tr></tbody></table></table-wrap></floats-group></article>